BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38252040)

  • 1. A win ratio-based framework to combine multiple clinical endpoints in exploratory basket trials.
    Zhang P; Li XN
    J Biopharm Stat; 2024 Mar; 34(2):251-259. PubMed ID: 38252040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints.
    Chi X; Yuan Y; Yu Z; Lin R
    Biom J; 2024 Mar; 66(2):e2300122. PubMed ID: 38368277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian basket trial design using a calibrated Bayesian hierarchical model.
    Chu Y; Yuan Y
    Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variance prior specification for a basket trial design using Bayesian hierarchical modeling.
    Cunanan KM; Iasonos A; Shen R; Gönen M
    Clin Trials; 2019 Apr; 16(2):142-153. PubMed ID: 30526008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors.
    Wang X; Wei W
    Contemp Clin Trials; 2024 May; 140():107505. PubMed ID: 38521384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian hierarchical models for adaptive basket trial designs.
    Chen C; Hsiao CF
    Pharm Stat; 2023; 22(3):531-546. PubMed ID: 36625301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian borrowing for basket trials with longitudinal outcomes.
    Whitehead LE; Sailer O; Witham MD; Wason JMS
    Stat Med; 2023 Jul; 42(16):2819-2840. PubMed ID: 37120858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian methods for the analysis of early-phase oncology basket trials with information borrowing across cancer types.
    Jin J; Riviere MK; Luo X; Dong Y
    Stat Med; 2020 Nov; 39(25):3459-3475. PubMed ID: 32717103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations.
    Asano J; Hirakawa A
    Pharm Stat; 2020 Nov; 19(6):975-1000. PubMed ID: 32779393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints.
    Chen N; Lee JJ
    Stat Methods Med Res; 2020 Sep; 29(9):2717-2732. PubMed ID: 32178585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing the efficiency of oncology basket trials using a Bayesian approach.
    Liu R; Liu Z; Ghadessi M; Vonk R
    Contemp Clin Trials; 2017 Dec; 63():67-72. PubMed ID: 28629993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An optimal two-stage exploratory basket trial design with aggregated futility analysis.
    Jing N; Liu F; Wu CI; Zhou H; Chen C
    Contemp Clin Trials; 2022 May; 116():106741. PubMed ID: 35358718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal two-stage designs for exploratory basket trials.
    Zhou H; Liu F; Wu C; Rubin EH; Giranda VL; Chen C
    Contemp Clin Trials; 2019 Oct; 85():105807. PubMed ID: 31260789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monotonicity conditions for avoiding counterintuitive decisions in basket trials.
    Baumann L; Krisam J; Kieser M
    Biom J; 2022 Jun; 64(5):934-947. PubMed ID: 35692061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints.
    He T; Liu R; Liu M; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):567-581. PubMed ID: 36000260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A frequentist design for basket trials using adaptive lasso.
    Kanapka L; Ivanova A
    Stat Med; 2024 Jan; 43(1):156-172. PubMed ID: 37919834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy.
    Zheng H; Wason JMS
    Biostatistics; 2022 Jan; 23(1):120-135. PubMed ID: 32380518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian basket trial design with false-discovery rate control.
    Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
    Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.